Search

everythinglearnresearchcommunity

for

Search:↓

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Leflunomide successfully treated a rare skin condition in a liver transplant patient.

Repurposing existing drugs can improve cancer treatment but faces challenges.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.

Topical ruxolitinib quickly improves non-segmental vitiligo.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Clofazimine may be effective for treating ashy dermatosis.

Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.

Ritlecitinib works well and is safe for treating alopecia areata.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Tigason improved hair growth in a boy with monilethrix without side effects.

Bicalutamide may effectively treat female pattern hair loss with minimal side effects.

The combination therapy was effective and well-tolerated, especially in young patients.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Ritlecitinib can help about 14,000 people with severe hair loss.

Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.

Topical imiquimod use for treating a cervical lesion might cause delayed hair loss.

MTX and GC combinations are the most effective for early rheumatoid arthritis.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.